BioCentury on BioBusiness, Analyst Picks & Changes
Analyst picks & changes
Published on Monday, July 12, 2010
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
7/9
cls
|
|
Affymetrix
Inc. (NASDAQ:AFFX)
|
UBS
|
Derik
de Bruin
|
Price
target
|
Neutral
|
-35%
|
$3.80
|
|
de
Bruin lowered his target to $4.50 from $7 after Affymetrix reported lower
than expected preliminary 2Q10 sales revenue of $71-$72M, below the previous
guidance of $80-$82M. The company cited slower instrument uptake and a
decline in RNA product sales related to the integration of recent
acquisitions and realignment of sales territories. de Bruin also lowered his
FY10 and FY11 sales estimates to $307M and $326M, respectively, from $339M
and $356M (see "Suffering from Austerity," A20).
|
97 words displayed of 406 words total.
Get the Full Text...
All contents Copyright © 1993-2012 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Purchase This Article
Learn what you're missing.
Broaden your Knowledge Base
The BioCentury Publications Package provides the essential coverage and analysis required by global biopharma decision makers.
Take advantage of our free trials and discover why BioCentury is the choice of biopharma professionals around the globe.
Free Trials Begin the Week Following Sign-up
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your records.
close [ X ]